Pages that link to "Q42284617"
Jump to navigation
Jump to search
The following pages link to Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. (Q42284617):
Displaying 50 items.
- Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications (Q21129423) (← links)
- Striatal cholinergic interneuron regulation and circuit effects (Q26863113) (← links)
- Therapy for Parkinson's disease: what is in the pipeline? (Q26991826) (← links)
- The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat (Q28368762) (← links)
- The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study (Q28477041) (← links)
- Auditory Rehabilitation in Rhesus Macaque Monkeys (Macaca mulatta) with Auditory Brainstem Implants. (Q30385023) (← links)
- Animal models of neurological deficits: how relevant is the rat? (Q31091605) (← links)
- Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism (Q34070904) (← links)
- The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies (Q34120740) (← links)
- Reliability and validity of a new global dyskinesia rating scale in the MPTP-lesioned non-human primate (Q34214529) (← links)
- The ?2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats (Q34270929) (← links)
- Pathophysiology of levodopa-induced dyskinesia: potential for new therapies (Q34325365) (← links)
- Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease (Q34572608) (← links)
- Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. (Q35003086) (← links)
- Noradrenaline and Parkinson's disease (Q35013240) (← links)
- The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates (Q35042094) (← links)
- Striatal glutamatergic mechanisms and extrapyramidal movement disorders (Q35165439) (← links)
- Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease (Q35196411) (← links)
- Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia (Q35324977) (← links)
- Present and future drug treatment for Parkinson's disease (Q35484805) (← links)
- Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats. (Q35624275) (← links)
- Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus (Q35738678) (← links)
- Novel pharmacological targets for the treatment of Parkinson's disease (Q36610996) (← links)
- Drug Insight: new drugs in development for Parkinson's disease (Q36631654) (← links)
- Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain (Q36851713) (← links)
- Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors? (Q37077360) (← links)
- Non-dopaminergic treatments in development for Parkinson's disease (Q37291597) (← links)
- The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future (Q37796015) (← links)
- Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. (Q37924629) (← links)
- Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease (Q38056852) (← links)
- The serotonergic system in motor and non-motor manifestations of Parkinson's disease (Q38118061) (← links)
- Non-dopaminergic treatments for motor control in Parkinson's disease (Q38126817) (← links)
- Role of metabotropic glutamate receptors in the regulation of pancreatic functions (Q38172715) (← links)
- Therapeutic potential of targeting glutamate receptors in Parkinson's disease. (Q38190016) (← links)
- Advances in non-dopaminergic treatments for Parkinson's disease (Q38218083) (← links)
- Molecular imaging of levodopa-induced dyskinesias. (Q38355582) (← links)
- Preclinical Evidence for a Role of the Nicotinic Cholinergic System in Parkinson's Disease (Q38629277) (← links)
- Endogenous dopaminergic tone and dopamine agonist action (Q39426348) (← links)
- Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease (Q41509268) (← links)
- Metabotropic glutamate receptors for Parkinson's disease therapy (Q41818450) (← links)
- Contrast optimization of Macaca mulatta basal ganglia in magnetic resonance images at 4.7 Tesla (Q42505353) (← links)
- Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease (Q42541635) (← links)
- Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys (Q42552539) (← links)
- Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease (Q42553008) (← links)
- CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study (Q42573127) (← links)
- Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial (Q42922693) (← links)
- Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. (Q43693346) (← links)
- Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease (Q43693354) (← links)
- Topographical Organization of Opioid Peptide Precursor Gene Expression Following Repeated Apomorphine Treatment in the 6-Hydroxydopamine-Lesioned Rat (Q44348262) (← links)
- Activation of subthalamic alpha 2 noradrenergic receptors induces motor deficits as a consequence of neuronal burst firing (Q44507281) (← links)